Merck (NYSE:MRK) is restructuring its pharmaceutical business into two divisions, Oncology and Specialty/Pharma & Infectious Diseases, with new executive leadership. The move is described as a ...
Zacks Investment Research on MSN
Can Merck's new drugs & pipeline ease Keytruda LOE concerns?
Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its ...
MRK's Keytruda posted $31.7B in 2025 sales. Can new approvals, ongoing studies and a revamped structure keep oncology growth strong through 2026?
Merck said on Monday it would split its business into two, creating a division for its cancer franchise while grouping its non-oncology treatments separately.
Merck & Co., Inc. (NYSE:MRK) has been on a strong recovery run, gaining 23% over the past year and 8% year-to-date, though ...
RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-B15 trial (also known as EV-304) in ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
KEYTRUDA monotherapy now approved as neoadjuvant treatment, continued as adjuvant treatment combined with radiotherapy with or without concomitant cisplatin then as monotherapy Based on results of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results